Bmes meet the faculty candidate 2012 ford

The Biomedical Engineering Society Annual Meeting in Tampa kicked off Wednesday, Meet the Faculty Candidates poster session draws hundreds. The "Meet-the-Faculty Candidate" poster session will provide a great opportunity for faculty, recruiters, and Department Chairs to speak directly with current. At the undergraduate level, the emphasis chosen by our faculty is, first and foremost, to provide students with cal school, or a position in industry. Multiple BME professors use ford University, Cedric F. Tulane University,

Duties included teaching, holding office hours and grading lab reports. Recognized by the VP for academic affairs, UConn, Storrs, for excellent teaching based on student evaluations. Lab assistant for field ornithology class, Center for Students with Disabilities, University of Connecticut June-July Aided a visually-impaired student with his field ornithology class.

These platforms offer the unique ability to follow intracellular drug trafficking and enzymatic cleavage in real time.

The broad-ranging application of this technology to clinical medicine, biochemical research, and peptide-based nanoparticle development led us to file a patent application. During my doctoral research, I designed and synthesized self-assembling peptide sequences to generate targeted structures in both organic solvents and water via the specific interactions of rationally designed amino acid sequences.

I was awarded a patent for my innovative work in graduate school, which produced a novel bottom-up synthesis method for peptide template-directed selfassembled mineralization, generating one-dimensional inorganic nanostructures.

These experiences shaped my future research goals: In self-assembly processes, fundamental building blocks organize themselves into functional structures as driven by the physicochemical properties of the system. Sufficient combinations of rationally placed interactions can produce the reversible self-assembly of stable structures, with these structures presenting a highly tunable and modular platform for a variety of applications.

I will use these powerful methodologies to surmount the key challenges for peptide-based therapeutics, diagnostics, and delivery platforms. Furthermore, I will use these approaches to elucidate the fundamental properties of self-assembling systems, in order to push the boundaries of molecular science.

I have demonstrated this approach to bone and lymph node targeting, which is a critical challenge in the treatment of cancer. I am currently using these strategies to advance stem cell based therapies by developing theranostic NPs that improve MSC differentiation and enable imaging based monitoring of their in vivo fate.

I am also developing drug delivery systems to improve natural killer cell based cancer immunotherapy. In the future, I plan to develop a diagnostic platform based on the sugar melibiose that can be detected in urine and will incorporate an imaging and drug delivery component.

Evaluation of cancer cell evasion of natural killer cells using a 3D tumor model. Formulation and evaluation of NPs to deliver microrna to natural killer cells.

Novel NPs to treat bone metastasis.

Optical mapping of blood brain barrier leakage after stroke. My doctoral work has focused primarily on the development of biomaterials for applications in tissue engineering and regenerative medicine. In this research I have successfully worked with a broad range of collaborators, including experts in cell biology, agent based modeling, molecular imaging, engineering and surgery.

This work has already resulted in 8 manuscripts, 1 book chapter, 2 manuscripts under review and 3 additional manuscripts in preparation. Overall, I would categorize the accomplishments of my research in the following areas: Biomaterials for Cell Delivery: Vehicles in Regenerative Medicine. Biomaterials with persistent growth factor gradients in vivo accelerate vascularized tissue formation. Design of a composite biomaterial system for tissue engineering applications.

Pore interconnectivity influences growth factor mediated vascularization in sphere template hydrogels. Tissue Engineering Part C: Methods, August21 8: Gradient scaffolds with ceramic augment bone formation in a periosteum guided bone model. My research interests span both basic and applied research areas.

My PhD dissertation developed modular systems using ECM materials to fabricate perfusable tissue constructs. I successfully fabricated a prototype, engineered liver tissue, formed by fusion of hepatocytecontaining microcapsules.

As part of my postdoc research, I developed an injectable bone scaffold which supported new bone formation in mice calvarial defects. There is also a need for enabling technologies for prevascularization of engineered constructs and for revival of ischemic tissues. I developed a microscale approach to control spatial distribution of cells and polysaccharide matrices which yielded tissue constructs with endothelialized interconnected channels which accelerated in vivo remodeling.

Further, I developed a minimally-invasive approach for enabling vascularization of ischemic tissues, by developing fibrin based microtissues that concentrate vasculogenic cells while promoting their vasculogenic potential.

My future goal is to utilize these strategies to fabricate implantable vascularized organs and to develop 3D organotypic models such as organ-on-chip for drug testing and basic research. My research work also include modulating innate immunity for directing cell function and response. From a tissue engineering perspective, guiding cellular phenotype and subsequent engraftment with the host are critical for the successful tissue regeneration.

To that end, I am developing strategies to modulate macrophage phenotype and subsequent mesenchymal stem cell function for tissue maturation and engraftment. I demonstrated polarization and osteogenesis inducing potential of pro-inflammatory macrophages and currently validating their in-vivo potential. Overall, the aforementioned research projects embody my long-term goals and future plans in basic and translational research for developing biomaterials-assisted and cell-based therapies for various diseases and disorders.

BTech Bachelor of Technology in Biotechnology, 1st class with distinction. Rumble University Graduate Fellow: Collagen Type II enhances chondrogenic differentiation in agarose-based modular microtissues.

Macrophages mediated degradation and release of BMP2 from gelation microspheres for bone regeneration. My group is exploring soft tissue behaviour, in particular that of the lungs, with the aim of characterising strain rate sensitivity, structural response in trauma, failure modes and residual function post-trauma.

The trauma of interest is blast and through developing good understanding of tissue response, novel and targeted protective measures can be developed. This forms the other half of my research focused on materials such as sandwich composites for use in large-scale protective structures as well as personal protective equipment i.

Brandon Baier – Page 2 – Biomedical Engineering at the University of Michigan

We develop and use various experimental techniques as well as numerical methods in our research, including: Full-scale explosives testing; Shock tubes and other gas gun facilities; Various conventional materials testing machines; Drop towers, Split Hopkinson Pressure Bars; High speed photography; Image Correlation; Structural integrity evaluation tools such as micro-ct, optical in-house serial sectioning tools for soft tissue, the Histocutter and acoustic measurements; Lung mechanics; and Numerical modelling of deformation, fluid-structure interaction and failure.

Part A, 42,journal articles, 3 book contributions, over 60 conference proceedings plus 5 more articles in or near submission. However, the large number of animals per assay, complexity of protocols, and sensitivity to environmental perturbations render research on C. During my post-doc at Georgia Tech, I have exploited the possibilities of microfluidics to enable traditionally challenging types of screens on first larval stage L1 and adult nematodes. The study of first larval stage C. I overcame this challenge by developing a microfluidic platform that uses nanoliter droplets of a reversible hydrogel to offer advanced manipulation of individual animals.

This work paves the way for high-throughput screening of L1 nematodes with high-resolution imaging and will facilitate the study of post-embryonic development. I have also developed a microfluidic platform for combinatorial drug screening of adult nematodes. Due to the exponential increase of combinations with the number of individual components, traditional technologies require a large amount of chemicals rendering the screens impractical.

I solved this bottleneck by creating a droplet-on-demand platform that enables the preparation of precise mixtures of reagents while handling nanoliter volumes and the delivery of the stimuli to the animals in a robust way.

Such a platform offers the possibility of performing combinatorial screens of rare compounds and identify therapeutic strategies. In the future, I plan on building on my experience with C. In addition, I intend to expand this approach to zebrafish, which will lead to an increase in throughput of assays by several orders of magnitude and open new exciting possibilities Ph. Lu, Hydrogel-droplet microfluidic platform for high-resolution imaging and sorting of early larval Caenorhabditis elegans, Lab on Chip 6, front cover; highlighted on the website of HFSP 2.

Garcia, Microfluidic-based generation of size-controlled, biofunctionalized synthetic polymer microgels for cell encapsulation, Advanced Materials 19 ; A. Lu, A perspective on optical developments in microfluidic platforms for Caenorhabditis elegans research, Biomicrofluidics 8 G. Haghiri-Gosnet, A multicolor microfluidic droplet dye laser with single mode emission, Applied Physics Letters, 98 G.

As a graduate student at the University of Iowa, I studied the response of metastatic tumor cells to fluid shear forces encountered during blood-borne circulation. This work revealed a fundamental link between oncogenic signaling and fluid shear stress survival, and led to a US Patent for our shear stress model. Having developed a keen interest in the mechanics of tumor biology, I joined the lab of Dr. Here, my project focuses on the physical landscape of the brain tumor microenvironment.

As the PI of an NIH-funded fellowship, my data has provided a mechanistic link between tumor cell-autologous ECM production, tissue stiffening, and mechanical signaling in the pathogenesis of high grade brain tumors glioblastoma. The scale of this project ranges from the molecular including bioluminescence imaging, fluorescence and atomic force microscopy to the cellular culture systems that model normal and diseased brain tissue mechanics to the organismal level, where we have developed novel glioblastoma mouse models in which mechanical signaling can be regulated.

Weaver and I are preparing to submit a manuscript on this work, and my collaborative contributions outside of this project will result in publications in the fields of fibrosis, cancer, and bioengineering. I am beginning to apply for academic positions, where I plan to continue studying the brain tumor microenvironment from a multi-disciplinary perspective. My graduate and postdoctoral training has prepared me to achieve this goal.

In addition to becoming proficient at many laboratory techniques, I have gained extensive experience in scientific writing and speaking and have built an incredible network of basic and clinical researchers in chemical and bioengineering, pathology, and oncology.

Resistance to fluid shear stress is a conserved biophysical property of malignant cells. On the biomedical front, the models will be used to design effective drug combination therapies for cancer and infectious diseases that have enhanced efficacy, diminished side effects, and reduced potential for developing drug resistance.

Scott Lempka Assistant Professor Neurostimulation for Chronic Pain Scott Lempka joins BME with the goal of partnering with physicians who both treat and research chronic pain to help elucidate how neurostimulation acts on chronic pain.

He does this by combining patient-specific computer models with clinical data, such as quantitative sensory testing and functional neuroimaging, to understand the effects of various therapies — why they work in some patients and not in others.


This experience provided him with a skill set for investigating the mechanisms of action of neurostimulation for neurological disorders. Many remain on disability, with great personal and societal costs. Using a systems biology approach, his lab aims to identify the critical metabolic regulators of cancer metastasis and the role the tumor microenvironment plays in modulating cancer cell metabolism. After completing his PhD from Rensselaer Polytechnic Institute in the area of chromatographic separations, Nagrath joined Harvard Medical School for a postdoc in metabolic and tissue engineering.

He then served as an assistant professor at Rice University focused on the systems biology of human disease. Here he mentored students in applying metabolic tracing techniques in cancer metastasis, uncovering metabolic approaches for targeting the tumor microenvironment, and unraveling the metabolic role of exosomes. And in Molecular Systems Biology, they showed that invasive ovarian cancer cells are glutamine-dependent and that glutamine selectively supports high-invasive versus low-invasive ovarian cancer cell growth through glutaminolysis and STAT3 signaling.

He is also eager to collaborate with immunologists to decipher metabolic targets for immunotherapy. Weiland investigates the fundamental mechanisms through which implantable and wearable electronic systems interact with the visual system and other senses, as well as the long-term consequences of such systems on the functional and anatomical organization of the visual system.

Based on this understanding, his lab creates and optimizes medical devices designed to improve the quality of life for the visually impaired. The main projects in his lab include a bioelectronic retinal prosthesis and wearable smart camera. The prosthesis, called the Argus II or bionic eye, provides electrical stimulation to the retina and can offer partial vision restoration to adults with profound blindness. Weiland has been involved in both its preclinical development and clinical testing, and hopes to improve upon the technology, providing greater visual enhancement to users.